Real-world study of cabozantinib in patients with advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy (CASSIOPE): interim data for patients who had received prior nivolumab

被引：0
|
作者：
Hamberg, Paul [1 ]
Bigot, Pierre [2 ]
Suarez, Cristina [3 ,4 ]
Barthelemy, Philippe [5 ]
Eymard, Jean-Christophe [6 ]
Masini, Cristina [7 ]
Gajate, Pablo [8 ]
Dutailly, Pascale [9 ]
Perrot, Valerie [9 ]
Procopio, Giuseppe [10 ]
机构：
[1] Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands
[2] Ctr Hosp Univ Angers, Angers, France
[3] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Med Oncol, Barcelona, Spain
[4] Vall dHebron Inst Oncol VHIO, Med Oncol, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
[5] Inst Cancerol Strasbourg Europe, Strasbourg, France
[6] Inst Jean Godinot, Reims, France
[7] AUSL IRCCS Reggio Emilia, Oncol Unit, Reggio Emilia, Italy
[8] Hosp Univ Ramon & Cajal, Madrid, Spain
[9] Ipsen, Boulogne Billancourt, France
[10] Fdn IRCCS, Ist Nazl Tumori, Milan, Italy
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
222
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [1] Real-world study of cabozantinib in patients with advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy (CASSIOPE): Interim data for patients who had received prior nivolumab
    Procopio, G.
    Hamberg, P.
    Bigot, P.
    Suarez Rodriguez, C.
    Barthelemy, P.
    Eymard, J-C.
    Masini, C.
    Gajate Borau, P.
    Dutailly, P.
    Perrot, V.
    Staehler, M.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S695 - S696
  • [2] Interim analysis of CASSIOPE: A real-world study of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy in Europe
    Procopio, G.
    Hamberg, P.
    Bigot, P.
    Suarez, C.
    Barthelemy, P.
    Eymard, J-C.
    Masini, C.
    Borau, P. Gajate
    Dutailly, P.
    Perrot, V.
    Staehler, M.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S571 - S571
  • [3] CASSIOPE: A real-world study assessing the use of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after vascular endothelial growth factor (VEGF)-targeted therapy in Europe
    Staehler, Michael D.
    Hamberg, Paul
    Bigot, Pierre
    Suarez, Cristina
    Barthelemy, Philippe
    Eymard, Jean-Christophe
    Laramas, Mathieu
    Pioger, Naila Taguieva
    Gross-Goupil, Marine
    Rink, Michael
    Masini, Cristina
    De Vivo, Rocco
    Gajate, Pablo
    Azzabi, Ashraf
    Procopio, Giuseppe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [4] CASSIOPE: A prospective noninterventional study of cabozantinib treatment following prior vascular endothelial growth factor (VEGF) -targeted therapy in patients with advanced renal cell carcinoma (aRCC).
    Staehler, Michael D.
    Bigot, Pierre
    Barthelemy, Philippe
    Hamberg, Paul
    Suarez, Cristina
    Eymard, Jean-Christophe
    Gajate, Pablo
    Perrot, Valerie
    Qvick, Bryan
    Dutailly, Pascale
    Procopio, Giuseppe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison
    Santoni, Matteo
    Aurilio, Gaetano
    Massari, Francesco
    Grande, Enrique
    Matrana, Marc R.
    Rizzo, Mimma
    De Giorgi, Ugo
    Incorvaia, Lorena
    Martignetti, Angelo
    Molina-Cerrillo, Javier
    Zabalza, Ignacio Ortego
    Mollica, Veronica
    Rizzo, Alessandro
    Battelli, Nicola
    Porta, Camillo
    [J]. CLINICAL GENITOURINARY CANCER, 2022, 20 (03) : 285 - 295
  • [6] Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma after Prior Therapy: Interim Results from the Noninterventional NORA Study
    Grimm, Marc-Oliver
    Gruenwald, Viktor
    Mueller-Huesmann, Harald
    Ivanyi, Philipp
    Schostak, Martin
    von der Heyde, Eyck
    Schultze-Seemann, Wolfgang
    Belz, Hanjo
    Bogemann, Martin
    Wang, Meng
    Herber, Martin
    Bedke, Jens
    [J]. EUROPEAN UROLOGY FOCUS, 2022, 8 (05): : 1289 - 1299
  • [7] Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study
    Barthelemy, P.
    Albiges, L.
    Escudier, B.
    Narciso, B.
    Bigot, P.
    Chehimi, M.
    Emambux, S.
    Calcagno, F.
    Mouillet, G.
    Eymard, J. -c.
    Schlurmann, F.
    Bailly, S.
    Garbay, D.
    Berdah, J. -F.
    Palmaro, M. B.
    Goupil, M. G.
    Spaeth, D.
    Nere, S.
    Quentric, C.
    Vano, Y. -A.
    Thiery-Vuillemin, A.
    [J]. ESMO OPEN, 2024, 9 (07)
  • [8] COST-EFFECTIVENESS IN ENGLAND OF CABOZANTINIB FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (ARCC) AFTER FAILURE OF PRIOR THERAPY
    Lister, J.
    Vataire, A.
    Amzal, B.
    Dinet, J.
    Meng, J.
    Karcher, H.
    Gabriel, S.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A441 - A441
  • [9] REAL-WORLD OUTCOMES AMONG PATIENTS WHO INITIATED PAZOPANIB OR SUNITINIB AS FIRST TARGETED THERAPY FOR ADVANCED RENAL CELL CARCINOMA (ARCC): A RETROSPECTIVE ANALYSIS OF MEDICARE DATA
    Vogelzang, N. J.
    Ghate, S. R.
    Li, N.
    Swallow, E.
    Peeples, M.
    Zichlin, M. L.
    Meiselbach, M. K.
    Perez, J. R.
    Agarwal, N.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A92 - A92
  • [10] Retrospective Analysis of the Safety and Efficacy of Interleukin-2 After Prior VEGF-targeted Therapy in Patients With Advanced Renal Cell Carcinoma
    Cho, Daniel C.
    Puzanov, Igor
    Regan, Meredith M.
    Schwarzberg, Talya
    Seery, Virginia
    Lee, Mee-Young
    Liu, Vivian
    Bhatt, Rupal
    Koon, Henry
    Mier, James W.
    Sosman, Jeffrey A.
    Atkins, Michael B.
    McDermott, David F.
    [J]. JOURNAL OF IMMUNOTHERAPY, 2009, 32 (02) : 181 - 185
12345